GeneOne Life Science Inc

GeneOne Life Science, Inc. is a biopharmaceutical company that researches, develops, and contract-manufactures nucleic acid-based biopharmaceuticals. Its pipeline includes small molecules such as GLS-1027 in Phase I for nephropathy and inflammatory diseases, GLS-1200 in Phase II for rhinosinusitis, and GLS-1027 and GLS-1200 in Phase II for COVID-19. Its nucleic acid vaccines include GLS-3000 mRNA under feasibility study, GLS-5310 DNA in Phase II for SARS-CoV-2, GLS-5100 in pre-clinical stage for herpes zoster prevention, and GLS-5140 in pre-clinical stage for SFTS prophylaxis. It is also developing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, GLS-6150 in Phase I for hepatitis C re-infection prophylaxis, and GLS-6100 in pre-clinical stage for hepatitis C prophylaxis. Its discovery and optimization pipeline includes GLS-7000 for breast cancer, GLS-7100 for hemophilia A, GLS-8000 for chronic hepatitis B prevention, and GLS-8100 for rheumatoid arthritis. The company also engages in cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. Formerly known as VGX International Inc., it changed its name to GeneOne Life Science, Inc. in April 2014. Founded in 1976, it is headquartered in Seoul, South Korea.